Boyapati A, et al. High Baseline Serum IL-6 Identifies a Subgroup of Rheumatoid Arthritis Patients with Rapid Joint Damage and Clinical Progression and Predicts Increased Sarilumab Treatment Response. ACR 2018, abstract L08.
Bimekizumab bij actieve axSpA: effectiviteit en veiligheid over 52 weken
jan 2024 | Spondyloartritis